Laguna Hills-based Glaukos Corp. has filed plans to raise $86 million in an initial public offering.
Glaukos makes the iStent, which is implanted in the eye to treat glaucoma, a major cause of blindness.
It plans to list its shares on the New York Stock Exchange.
The company’s investors include Versant Ventures, a venture capital firm that is based in Menlo Park and has an office in Newport Beach.
